STAGE IV PROSTATE CANCER AJCC V8
Clinical trials for STAGE IV PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation approach aims to tame recurrent prostate cancer with fewer side effects
Disease control OngoingThis study tests two types of radiation therapy—proton beam and IMRT—given in shorter courses for men whose prostate cancer has come back and spread only to pelvic or abdominal lymph nodes. The goal is to see if the shorter treatment is safer and causes fewer severe side effects.…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
New combo aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control TerminatedThis study tests whether combining two drugs, vidutolimod and nivolumab, can help the immune system find and destroy prostate cancer cells that have spread. It is for men whose cancer has stopped responding to standard hormone therapy and chemotherapy. The goal is to see if this …
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
Prostate cancer patients may get a break from hormone therapy in new trial
Disease control OngoingThis study looks at whether men with metastatic prostate cancer that responds extremely well to hormone therapy can safely take a break from treatment. The goal is to see if their testosterone levels can recover and how long they can stay off therapy without the cancer worsening.…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
New Triple-Drug combo targets advanced prostate cancer before hormone treatment
Disease control OngoingThis phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naive prostate cancer that has spread. The goal is to see how long patients can stay on treatment and how well it controls the cancer. Participants must have high-risk featur…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control OngoingThis study tests two drugs, golimumab and apalutamide, in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if blocking inflammation and male hormones together can shrink tumors or slow the cancer. Eight men partic…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug cocktail shows promise in slowing tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo therapy aims to shrink advanced cancers
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other drugs and radiation in people with advanced cancers that have not responded to standard treatments. About 173 adults with various solid tumors, including prostate cancer, will re…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug cocktail shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new drug (berzosertib) combined with standard chemotherapy (carboplatin) in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if this combination shrinks tumors or lowers PSA l…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough prostate cancer: Two-Drug attack after chemo
Disease control OngoingThis study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE IV PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC